NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 12:30
Last Report Issued 05/11/2016 09:41

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2457SP
Patient ID 2457SP
Chain 16000652
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 16000652

Received 05/04/2016 13:31

Sample ID 16000652-001
Matrix Serum or Plasma
Patient Name 2457SP
Patient ID 2457SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
2457SP Isavuconazole, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Isavuconazole	None Detected	mcg/mL	0.050	
Synonym(s): BAL4815; BAL8557; Cresemba®				
Single oral doses of 100, 200, and 400 mg of isavuconazole as a prodrug resulted in peak plasma concentrations of 1.45 (+/- 0.177) mcg/mL, 2.59 (+/- 0.449) mcg/mL, and 5.57 (+/- 0.212) mcg/mL, respectively. Peak plasma concentrations were reached between 1.8-3 hrs after administration.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.